Allena Pharmaceuticals to Present at Upcoming Investor Conferences in January

Rhea-AI Summary

Allena Pharmaceuticals (NASDAQ: ALNA) announced participation in two investor conferences in January 2021. CEO Louis Brenner will host a pre-recorded fireside chat available on-demand from January 11, 2021, at 6:00 a.m. ET during the H.C. Wainwright Bioconnect 2021 Conference. Additionally, he will present at the 15th Annual Stern IR Corporate Access Event, with a corporate overview available from 7:00 a.m. ET on the same day. One-on-one meetings will occur from January 11-14, 2021. Presentations can be viewed on their website.

NEWTON, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in two upcoming investor conferences in January:

H.C. Wainwright Bioconnect 2021 Conference

• Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will participate in a pre-recorded fireside chat, which will become available for on-demand viewing at 6:00 a.m. ET on Monday, January 11, 2021.
  

15^th Annual Stern IR Corporate Access Event

• Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will pre-record a corporate overview, which will become available for on-demand viewing at 7:00 a.m. ET on Monday, January 11, 2021. Management will also be available for one-on-one meetings from Monday, January 11-Thursday, January 14, 2021.
  

The presentations will be available for on-demand viewing under “Events and Presentations” in the Investors section of the Company’s website at www.allenapharma.com. Replays of the webcasts will be available on the Allena website for approximately 30 days.

About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with Phase 1b multiple-ascending dose and Phase 2 proof-of-concept studies planned for 2021.

Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com

FAQ

What conferences will Allena Pharmaceuticals participate in January 2021?

Allena Pharmaceuticals will participate in the H.C. Wainwright Bioconnect 2021 Conference and the 15th Annual Stern IR Corporate Access Event.

When will Allena's CEO present at the conferences?

CEO Louis Brenner will present at both conferences on January 11, 2021.

Where can I find the presentations from Allena Pharmaceuticals?

The presentations will be available under 'Events and Presentations' in the Investors section of Allena Pharmaceuticals' website.

What is the focus of Allena Pharmaceuticals' product candidates?

Allena focuses on developing oral enzyme therapeutics for rare and severe metabolic and kidney disorders.

What is reloxaliase and its current status?

Reloxaliase is Allena's lead product candidate, currently in a pivotal Phase 3 clinical program for treating enteric hyperoxaluria.